Skip to main content
Clinical Trials/NCT02663921
NCT02663921CompletedNot Applicable

Determination of the Minimal Dose of Visible Light Required to Achieve Immediate Pigment Darkening, Persistent Pigment Darkening, and Delayed Tanning for Fitzpatrick Skin Types IV-VI Utilizing Two Visible Light Sources.

NYU Langone Health1 site in 1 country8 target enrollmentStarted: September 1, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
8
Locations
1
Primary Endpoint
Diffuse Reflectance Spectroscopy (DRS) to examine the optical properties of melanin and deoxyhemoglobin

Study Overview

Brief Summary

The purpose of this study is to learn more about the potential effects of visible light on the skin. More specifically, this study will examine whether an incandescent lamp (light bulb) or LED light bulb can cause skin to become darker. Investigators will determine the minimum threshold dose required to achieve immediate pigmentation darkening (IPD), persistent pigmentation darkening (PPD), and delayed tanning (DT) for Fitzpatrick skin types IV - VI utilizing two visible light sources.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Be a healthy volunteer with Fitzpatrick skin types I-VI;
  • •Agree to abide by the Investigator's guidelines regarding photosensitizing drugs and photoprotection;
  • •Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form;
  • •Agree to follow and undergo all study-related procedures.

Exclusion Criteria

  • •Women who are lactating, pregnant, or planning to become pregnant;
  • •Patients with a recent history of vitiligo, melasma, and other disorders of pigmentation with the exception of post-inflammatory hyperpigmentation;
  • •Patients with a known history of photosensitivity disorders;
  • •Photosensitizing medications may be continued throughout of the study at the discretion of the investigator ;
  • •Patients with a known history of melanoma or non-melanoma skin cancers;
  • •Concomitant use of tanning beds;
  • •Sun exposure of the irradiated or control areas;
  • •Patients with serious systemic disease.
  • •Patients with a known history of hypersensitivity to adhesives including adhesive tape.

Arms & Interventions

Healthy volunteers

Experimental

Healthy volunteers without cutaneous disorders associated with pigmentary changes

Intervention: Part A: Baseline-Week 2 (Other)

Healthy volunteers

Experimental

Healthy volunteers without cutaneous disorders associated with pigmentary changes

Intervention: Part B: Week 4-Week 12 (Other)

Outcomes

Primary Outcomes

Diffuse Reflectance Spectroscopy (DRS) to examine the optical properties of melanin and deoxyhemoglobin

Time Frame: 12 weeks

Measurement of pigmentation changes induced by the two light sources using Cross-Polarized Digital Photography

Time Frame: 12 weeks

Quantification of the scattering and absorption properties of the skin in which the beam of light will penetrate using DRS

Time Frame: 12 weeks

Measurement of pigmentation changes induced by the two light sources using Colorimetry

Time Frame: 12 weeks

Measurement of pigmentation changes induced by the two light sources using diffuse reflectance spectrometer

Time Frame: 12 weeks

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials